sever
recent
technolog
gener
human
monoclon
antibodi
mab
led
remark
result
treatment
cancer
inflammatori
meanwhil
use
mab
prevent
treat
infecti
diseas
much
notabl
except
mab
target
respiratori
syncyti
viru
recent
studi
natur
wrammert
et
describ
rapid
rout
obtain
fulli
human
highaffin
mab
influenza
viru
take
advantag
huge
surg
activ
transcrib
plasma
cell
author
show
specif
antibodi
clone
singl
cell
follow
recent
vaccin
initi
therapeut
mab
gener
mice
use
directli
human
often
practic
elicit
harm
human
antibodi
respons
prompt
effort
reengin
rodent
mab
somewhat
labori
look
like
human
antibodi
thu
attenu
advers
reaction
recent
improv
mab
isol
screen
technolog
provid
access
fulli
human
mab
one
major
approach
product
human
mab
display
technolog
librari
antibodi
display
surfac
host
phage
although
yeast
bacteria
mammalian
cell
ribosom
also
display
method
rel
access
also
allow
vitro
affin
improv
select
mab
potenti
drawback
method
possibl
unnatur
pair
antibodi
heavi
light
chain
compon
although
case
unlik
hindranc
advent
transgen
mice
engin
repertoir
fulli
human
gave
research
altern
rout
human
mab
activ
immun
without
protocol
restrict
associ
human
studi
transgen
mice
exactli
reproduc
human
antibodi
respons
repertoir
differ
genet
background
murin
host
affect
antigen
process
bcell
ontolog
regul
eg
toler
mechan
differ
may
advantag
disadvantag
depend
research
applic
whether
break
toler
particular
antigen
desir
present
transgen
mice
protect
intellectu
properti
therefor
commonli
avail
anoth
recent
methodolog
advanc
gener
human
mab
involv
improv
immort
human
memori
b
cell
presenc
epsteinbarr
viru
importantli
agent
activ
b
cell
tolllik
receptor
approach
use
identifi
neutral
mab
number
pathogen
includ
sar
coronaviru
avian
influenza
wrammert
et
focus
distinct
popul
antibodysecret
cell
asc
give
readi
access
human
mab
influenza
viru
sever
distinct
subpopul
asc
found
peripher
blood
includ
deriv
naiv
marginalzon
naiv
follicular
b
cell
shortliv
plasma
cell
plasma
cell
destin
longterm
resid
bone
asc
differenti
nonantibodysecret
memori
b
cell
probe
level
variou
cellsurfac
marker
use
flow
cytometri
wrammert
et
sort
earli
asc
gate
cell
subgat
number
asc
peak
around
day
short
burst
booster
immun
wane
rapidli
thereaft
fig
interestingli
influenzaspecif
igg
asc
respons
reach
total
b
cell
day
could
clearli
distinguish
influenzaspecif
igg
memori
b
cell
peak
later
day
averag
b
cell
high
frequenc
asc
peripher
blood
roughli
week
booster
immun
consist
observ
variou
antigen
tetanu
inde
first
fulli
human
mab
phage
gener
individu
boost
tetanu
toxoid
follow
librari
construct
use
peripher
blood
lymphocyt
isol
day
wrammert
et
also
found
peak
asc
respons
week
influenza
vaccin
pauciclon
consist
larg
antibodi
famili
base
singl
gene
rearrang
diversifi
somat
hypermut
thu
averag
asc
sort
flow
cytometri
assay
elispot
influenza
specif
interest
fluspecif
antibodi
unusu
high
rate
somat
mutat
half
fluspecif
asc
somat
mutat
wherea
quarter
memori
igg
b
cell
mutat
degre
ratio
cdrfwr
mutat
demonstr
approach
author
gener
panel
specif
antiinfluenza
mab
amplifi
immunoglobulin
variabl
region
asc
singlecel
revers
transcriptas
follow
subclon
final
protein
product
cell
screen
differ
influenza
strain
mab
found
highest
affin
immun
vaccin
strain
rather
strain
previous
encount
host
find
varianc
mechan
call
origin
antigen
sin
oa
elicit
antibodi
show
higher
affin
previous
encount
influenza
strain
vaccin
strain
result
wrammert
et
rather
support
mechan
wherebi
asc
highest
affin
antigen
preferenti
expand
techniqu
wrammert
et
eleg
conveni
product
mab
short
time
period
day
amen
mani
diseas
human
subject
follow
week
booster
immun
applic
human
mab
obtain
includ
therapi
condit
current
treat
polyclon
igg
immunocompromis
individu
vaccin
option
wrammert
et
identifi
highaffin
mab
sever
influenza
strain
although
specif
studi
avian
influenza
viru
repeatedli
trigger
major
intern
public
health
concern
aris
report
case
viral
genet
shift
bird
human
human
mab
may
also
nich
role
defend
threat
outbreak
caus
influenza
highli
virul
pathogen
subunit
vaccin
wide
avail
noteworthi
lethal
egg
howev
uncertainti
appli
method
wrammert
et
identifi
mab
chronic
latent
pathogen
notabl
hiv
well
cancer
autoimmun
diseas
day
asc
burst
readili
identifi
owe
chronic
bcell
stimul
clearli
interest
determin
method
wrammert
et
adapt
pathogen
target
applic
improv
method
like
come
rapidli
competit
access
speed
demand
human
mab
never
higher
